Loomis, Sayles & Company’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
Other funds holding NEO
FLAM
GF
NAMI
B
Loomis, Sayles & Company's NEO Position: Q2 2026 in Review
Loomis, Sayles & Company increased its NeoGenomics (NEO) stake by 30% in Q2 2026, buying an estimated $5.72M and bringing the position to 2,537,717 shares worth $37M. The position accounts for 0.05% of the portfolio, ranked #157.
Loomis, Sayles & Company first reported a position in NEO in Q1 2016 and has held it in 22 quarters since. The position peaked at $67.1M in Q4 2020. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.
- Loomis, Sayles & Company held 2,537,717 shares of NeoGenomics worth $37M as of Q2 2026.
- Loomis, Sayles & Company bought 592,329 NeoGenomics shares in Q2 2026, an estimated $5.72M.
- NeoGenomics made up 0.05% of Loomis, Sayles & Company's portfolio in Q2 2026, its #157 holding.
- Loomis, Sayles & Company first reported a position in NeoGenomics in Q1 2016 and has held it in 22 quarters since.
- Loomis, Sayles & Company's NeoGenomics position peaked at $67.1M in Q4 2020.
- 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.
Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.